Earnings Call · Q4 FY2024·2025-02-19

Q4 24EPS +10.67%·Rev n/aQ3 24EPS +0.51%·Rev n/aQ2 24EPS +2.91%·Rev n/aQ1 24EPS +2.83%·Rev n/a⚠ consensus missing

Karyopharm Therapeutics Inc. KPTI

Brendan Strong — Investor Relations or Communications

Richard Paulson — Chief Executive Officer

Reshma Rangwala — Chief Medical Officer or Head of Clinical Development

Sohanya Cheng — Head of Commercial or Commercial Leader

Lori Macomber — Chief Financial Officer

−6.4%1d on move date−6.5% vs SPY3d−11.5%5d−8.1%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more KPTI calls or request research access.

More KPTI calls Browse calls Request research access